Ptc Therapeutics (PTCT) Total Non-Current Liabilities (2012 - 2026)

Ptc Therapeutics' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 6.85% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $3.0 billion (up 6.85% YoY), while the FY2025 annual figure was $3.1 billion, up 10.28% from the prior year.
• Total Non-Current Liabilities was $3.0 billion for Q1 2026 at Ptc Therapeutics, down from $3.1 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $3.1 billion in Q4 2025 to a low of $1.7 billion in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $2.5 billion across 5 years, with a median of $2.7 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities declined 5.39% in 2022, then surged 54.07% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $2.1 billion in 2022, then soared by 32.39% to $2.7 billion in 2023, then advanced by 3.25% to $2.8 billion in 2024, then advanced by 10.28% to $3.1 billion in 2025, then retreated by 1.76% to $3.0 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $3.0 billion (Q1 2026), $3.1 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.